TMDC NZ with CAT-/SOD-like activity was used to mitigate the pathology of Alzheimer’s disease by targeting neuronal mitochondria with (3-carboxypropyl)triphenyl-phosphonium bromide-conjugated 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(PEG)-2000]-functionalized MoS2 QDs. The gene discussed is SOD1; the disease is early-onset autosomal dominant Alzheimer disease.